Nathan Latka

It was when we were just launching the show.

So I don't have a ton of data points from back then.

But most folks series a the past couple years, you know, you're selling, you know, 10 to 15% of the company, did you sort of do something standard, you were sort of in that same range?

Okay.

And same with Sir, you know, series B, you know, you're selling five to 10%, sort of in that same range.

Same thing.

Okay.

How do you think about Arrowroot coming in with 17 million in 2020?

It's not labeled as any kind of round and crunch base.

So how do you think about them?

Is that a series C?

Well, was it the same paper the series B set on or do they repaper the deal at a higher valuation?

Was a part of that Arrowroot deal secondary?

Was it all for operating capital?

Sorry, just to be clear, if you if you incentivize your early employees in 2015, with option grants, they've been waiting now for five years, it might be nice to create secondary for some of them.

So necessarily wasn't for you.

But have you created a liquidity opportunity for any of your early early employees who are incentivized with option grants?

Certainly not.

Interesting.

How did you how do you think about that moving forward?